The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Roca, C. A.
* Articles by Rubinow, D. R.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Roca, C. A.
* Articles by Rubinow, D. R.
Related Collections
* Premenstrual Dysphoric Disorder
* Symptoms/Dimensions
* Other Somatic Therapy
Am J Psychiatry 159:1876-1881, November 2002
© 2002 American Psychiatric Association


Article

Effects of Metergoline on Symptoms in Women With Premenstrual Dysphoric Disorder

Catherine A. Roca, M.D., Peter J. Schmidt, M.D., Mark J. Smith, M.D., Ph.D., Merry A. Danaceau, R.N., Dennis L. Murphy, M.D., and David R. Rubinow, M.D.

OBJECTIVE: The authors investigated the role of acute serotonergic modulation in the efficacy of selective serotonin reuptake inhibitors (SSRIs) in women with premenstrual dysphoric disorder. METHOD: Patients with premenstrual dysphoric disorder (whose symptoms had remitted during treatment with fluoxetine) and a group of unmedicated healthy comparison women received the serotonin receptor antagonist metergoline as part of a double-blind, placebo-controlled crossover study. RESULTS: The patients with premenstrual dysphoric disorder experienced a return of symptoms 24 hours after treatment with metergoline but not diphenhydramine (active placebo). The comparison women experienced no changes in mood. CONCLUSIONS: These data support the role of altered serotonergic transmission in the efficacy of SSRI treatment for premenstrual dysphoric disorder.




This article has been cited by other articles:


Home page
Adv. Psychiatr. Treat.Home page
C. A. Henshaw
PMS: diagnosis, aetiology, assessment and management: REVISITING... PREMENSTRUAL SYNDROME
Advan. Psychiatr. Treat., March 1, 2007; 13(2): 139 - 146.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
E. W. Freeman, K. Rickels, S. J. Sondheimer, M. Polansky, and S. Xiao
Continuous or Intermittent Dosing With Sertraline for Patients With Severe Premenstrual Syndrome or Premenstrual Dysphoric Disorder
Am J Psychiatry, February 1, 2004; 161(2): 343 - 351.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org